A 68-year-old woman with unstable angina and an episode of ventricular fibrillation developed a persistent and recurrent rash due to heparin. Medical therapy was continued with danaproid. For cardiopulmonary bypass and coronary artery grafting, r-hirudin was used as the anticoagulant. There were no thrombotic or coagulopathic complications. There is still no ideal alternative to unfractionated heparin for anticoagulation for cardiopulmonary bypass. The use of r-hirudin was successful and we describe our anticoagulant strategy.
Anticoagulation for cardiopulmonary bypass in the patient who is sensitive to heparin provides a challenge. None of the available alternatives is ideal, as all have potential haemorrhagic, thrombotic and logistic difficulties.
CASE REPORT
A 68-year-old woman weighing 74 kg, was admitted with unstable angina. She suffered an episode of ventricular fibrillation but was quickly resuscitated without sequelae. Cardiac catheter findings were a left main coronary lesion, ostial left anterior descending lesion with diseased circumflex and right coronary arteries. Left ventricular end diastolic pressure was 20 mmHg and ejection fraction was 54%. Acute coronary artery grafting was recommended. Despite her having had a nephrectomy, creatinine (0.067 mmol/l) and urea (4.0 mmol/l) were normal.
Medical therapy for the unstable angina included intravenous heparin which was associated with the development of a florid rash. The rash faded after cessation of unfractionated heparin and stabilisation on a low molecular weight heparin, enoxaparin (Clexane™, Aventis Pharma AG, Frankfurt, Germany). The rash recurred after rechallenge with unfractionated, preservative free heparin. Platelet counts remained normal. The patient found the rash very distressing and rejected heparin as an option for cardiopulmonary bypass. She was then stabilized on danaproid (Orgaran ™, NV Organon, Netherlands).
Haemorrhagic complications had marred our previous experience with danaproid as an anticoagulant for cardiopulmonary bypass.
The use of r-hirudin (Lepirudin, Refludan™, Aventis Pharma AG, Frankfurt, Germany) was planned for anticoagulation for cardiopulmonary bypass. Obtaining supplies required special arrangements, which we tried to accelerate due to the relatively urgent clinical situation. We obtained the drug in 10 days from John Bell, a pharmaceutical supply company in the United Kingdom.
The patient's baseline plasma ecarin clotting time was 16.9 seconds. In a control assay the ecarin clotting time increased in a linear manner with increasing concentrations of r-hirudin to 8 µg/ml for both patient's (r 2 =0.9924) and control (r 2 =0.9964) plasma ( Figure 1 ). A strategy of seeking anticoagulation for bypass at an ecarin clotting time prolonged 3.5 times baseline was pursued with dosages of r-hirudin based on those of Potzsch et al 1 . A system for optimal feedback of results was established with our coagulation laboratory, and most results were available in theatre within 25 minutes of drawing the blood.
Twenty-four hours pre-bypass, the danaproid infusion was stopped and r-hirudin introduced at a dosage of 5 mg/h. In the operating theatre the following day, after vein harvest and high dose aprotinin 2 (Trasylol™, Bayer AG, Leverkusen, Germany), a bolus dose of r-hirudin 25 mg (0.3 mg/kg) was given, the pump primed with a further 25 mg and an infusion commenced at 30 mg/h. The internal mammary artery was not dissected because of concern about bleeding complications. A further bolus dose of 20 mg was administered before the first result became available. Ecarin clotting time was prolonged to 92 seconds (time ratio 5.3) by the initial loading dose and cardiopulmonary bypass commenced (Table 1) . A Carmeda™ (Medtronic Inc, Minneapolis, U.S.A.) circuit and cardioplegia system with mild hypothermia (32°C) and crystalloid/Pentaspan™/mannitol prime was used. Saphenous vein coronary artery bypass grafting was performed and weaning from bypass was uneventful.
The r-hirudin infusion was stopped after separation from cardiopulmonary bypass and after 20 minutes clots began to appear in the surgical field. 
Concentration of r-hirudin (µg/ml)
Haemostasis appeared excellent and the chest was closed despite the ecarin clotting time remaining prolonged (57 seconds, time ratio 3.3). Bypass time was 78 minutes and the aortic cross clamp time 37 minutes. On disassembly of the bypass circuit after approximately 60 minutes of stasis, the circuit had clotted. The results of the measures of anticoagulation in the perioperative period are shown in Table 1 .
Postoperative mediastinal drainage remained light. After two hours in the intensive care unit, aspirin and danaproid infusion were reintroduced. Further recovery was uneventful apart from an episode of atrial fibrillation with symptomatic hypotension on the second postoperative day.
DISCUSSION
Unfractionated heparin is the optimal anticoagulant currently available for cardiopulmonary bypass, having multiple sites of action on platelet activation and thrombin generation and an effective reversal agent. Patients with unstable myocardial ischaemia are commonly treated with heparin for long periods. Heparin-induced thrombocytopenia, which may be associated with thrombotic complications, has been increasingly recognised. Alternatives to heparin for anticoagulation for cardiopulmonary bypass are required for patients with heparin sensitivity. Although our patient did not have heparin-induced thrombocytopenia, she preferred the risks of using a relatively untried agent to the risks of re-exposure to unfractionated heparin which had previously caused a severe skin reaction.
Several alternatives to heparin have been described. Doherty 3 has described the use of the heparinoid Orgaran 10172 (danaproid). However, both thrombotic and haemorrhagic complications have been noted by Insler 4 despite maintaining anti-Xa activity of greater than 1.25 U/ml as recommended by Doherty. Our experience is similar to that of Insler.
Other strategies include sequential defibrinogenation with ancrod and platelet inhibition with prostaglandin inhibitors (iloprost).
r-hirudin is a high-affinity and direct-acting thrombin inhibitor, derived from the saliva of leeches. Its use has been recently described 1,5-8 including a series of 21 patients. It is presented as a vial of 50 mg with a reasonable shelf-life. As activated partial thromboplastin time (APTT) and activated clotting time (ACT) are not thought to accurately reflect r-hirudin activity or concentrations, Potzsch et al 1 developed a whole blood assay based on the prothrombin activat-ing enzyme ecarin. Ecarin is a metalloproteinase enzyme derived from snake venom (Echis carinatin).
The specific assay of Potzsch et al 1 was not available to us. However the plasma ecarin clotting time is a standard laboratory test used to assess the presence of a warfarin effect or vitamin K deficiency (Echis ratio). With the laboratory's co-operation, we were able to obtain assay results within 20 to 25 minutes of drawing blood, allowing for assay times of up to 300 seconds (5 minutes), and centrifuge time of 10 minutes. This is clearly slower than the usual methods for monitoring heparin anticoagulation in the operating theatre, but was considered acceptable.
Potzsch et al 1 used an intravenous loading dose of 0.25 mg/kg of r-hirudin and 0.2 mg/kg to prime the extracorporeal circuit with repeated boluses of 5 mg, aiming for a target r-hirudin concentration of greater than 2.5 µg/ml. Koster et al 5 used similar loading doses with a continuous infusion, aiming for r-hirudin concentrations of 3.5 to 4 µg/ml. An r-hirudin concentration of 4 µg/ml produces a 3 to 4 fold prolongation from baseline of whole blood ecarin time 1 . This matched our assay of plasma ecarin clotting time. As this is analogous to the prolongation of ACT normally achieved with heparin, we decided to proceed, defining adequate anticoagulation for bypass as a prolongation of plasma ecarin clotting time to 3.5 times baseline.
Appropriate anticoagulation (Table 1) with r-hirudin was achieved with doses based on those of Potzsch et al. Due to the potentially catastrophic consequences of inadequate anticoagulation, we administered an additional bolus while waiting for the first assay result before initiating cardiopulmonary bypass. This relative overdose did not appear to have any adverse consequences, and haemostasis appeared excellent with clots forming within 20 minutes of stopping the r-hirudin infusion. As the residual blood in the pump had clotted when it was dismantled approximately one hour after cessation of bypass, it would seem prudent not to administer "pump blood" after any significant period of stasis. Latham et al 8 report similar clotting after administering similar doses of r-hirudin and aiming to prolong the APTT >100 seconds. The APTT results we recorded were generally in excess of 200 seconds throughout the bypass period and remained >100 seconds for three to four hours post bypass when the patient's coagulation had clinically returned to normal. The plasma ecarin clotting time was a little better than the APTT in reflecting the observed anticoagulant effect.
The 3.5 times prolongation of plasma ecarin time was an adequate level of anticoagulation but we would not contemplate accepting any lesser value. Although the ACT was prolonged in parallel with the ecarin clotting time, an ACT of greater than 400 seconds, our normal prerequisite for commencing bypass, was not achieved prior to bypass.
Clearance of r-hirudin from the circulation is dependent on normal renal function. Koster et al 5 report four out of four patients with preoperative creatinine of greater than 1.5 mg/dl (0.133 mmol/l) having excessive transfusion requirements and requiring re-exploration as opposed to none of 17 patients who had preoperative creatinine of less than 1.5 mg/dl (0.133 mmol/l). The Carmeda bypass circuit has a covalently bound heparin coating. Although no leaching of heparin is thought to occur, it may have been more prudent to use a completely heparin-free circuit. We avoided use of the mammary artery for grafting on this occasion, but would probably use it in a future patient treated with r-hirudin.
In summary, we report the use of r-hirudin as the anticoagulant for cardiopulmonary bypass in a woman with a severe heparin reaction who had declined further heparin exposure. The plasma ecarin clotting time proved an adequate means of monitoring r-hirudin levels, but is not ideal, due to the long processing time. The author is not aware of any previous use of r-hirudin for cardiopulmonary bypass in Australasia, or the use of plasma ecarin clotting time as the monitor of anticoagulant effect. Our institution now stocks sufficient r-hirudin for use in urgent cases where cardiopulmonary bypass is required and heparin needs to be avoided.
